News and Events

Upcoming Events
March 7, 2025
March 18 Communications Subcommittee Meeting
March 4, 2025
March 14 Governance Subcommittee Meeting
February 28, 2025
March 10 Accessibility and Affordability Working Group Meeting
February 21, 2025
March 5 Joint Science Subcommittee/Neuro Task Force Meeting
Latest Press Releases
January 31, 2025
CIRM Awards Nearly $100 Million to Boost Discovery, Translational, and Clinical Disease Research
November 21, 2024
CIRM Awards $29.7 Million to Advance Clinical Projects
November 14, 2024
CIRM marks 20 years of advancing regenerative medicine in California
September 27, 2024
CIRM Announces Recommendations from Strategic Allocation Framework
CIRM’s Blog: The Stem Cellar
The Stem Cellar
- Advancing Heart Health: CIRM Funds Tenaya Therapeutics’ Gene Therapy Trial for ARVC March 7, 2025The California Institute for Regenerative Medicine (CIRM) recently announced funding a series of projects spanning the earliest stages of research through to clinical trials. One of those projects was an $8 million award to Matthew Pollman, MD, MS, Senior Vice President of Clinical Development at Tenaya Therapeutics, to support a clinical trial focused on treating […]
- Honoring Dr. John Zaia: A Legacy of Science, Leadership, and Kindness February 27, 2025The scientific community lost a true pioneer with the passing of John A. Zaia, MD, a visionary virologist, gene therapy trailblazer, and esteemed leader at City of Hope. Dr. Zaia dedicated over four decades to advancing regenerative medicine, leaving a profound impact on HIV research, pediatric diseases, stem cell transplantation, and cell and gene therapy. […]
- FDA Grants RMAT Designation to Luxa Biotechnology’s CIRM-funded Dry AMD Therapy February 25, 2025The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for a project focused on vision loss that was funded in part by the California Institute for Regenerative Medicine (CIRM). This designation is given to highly promising regenerative medicine therapies that treat serious or life-threatening diseases with the goal of accelerating the path to FDA […]